BioSpace News Archive

Company Reports Third Quarter Revenues of $265.0 Million, GAAP Net Loss per Share of $0.00 and Basic and Diluted Non-GAAP Earnings per Share of $0.26

Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list.

Leading sports nutrition brand Novex Biotech alongside Authentic Brands Group (ABG), a global brand owner, marketing and entertainment company, today announced World Golf Hall of Fame member, Greg Norman, as its new Brand Ambassador representing Novex’s full product assortment

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020, before the U.S. financial markets open

Elpis Biopharmaceuticals today announced the closing of a $30 million Series A financing to propel solid tumor and hematological disease therapeutics through pre-clinical studies, which brings the company to a total of $40 million raised including seed funding.

Agency-wide CRADA agreement also includes studies with Brain-Chip in Alzheimer’s disease, Intestine-Chip in microbiome health, and Liver-Chip in individualized toxicity responses

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the company’s investigational gene therapy for the treatment of Fabry disease. AVR-RD-01, an ex-vivo, lentiviral gene therapy, consists of the patient’s own hematopoietic stem ce

Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi ® in Stage III NSCLC - Collaboration Further Strengthens Arcus’s Position at the Forefront of the Anti-TIGIT Field and Leverages AstraZeneca’s Leadership in the Curative-Intent Stage III NSCLC Setting - Registrational Trial for Domvanalimab plus Imfinzi Expected to Begin in 2021 - Further Builds on the Arcus-Gilea

Indivior PLC (LON: INDV) today announced that financial results for the third quarter and nine months period ended September 30, 2020 , including the press release and investor supplement, are now available on the Group’s website at www.indivior.com .

First-in-class interoperability, data sharing and engagement platform, integrated at the core, unlocking global patient insights and experiences